在患有充血性心力衰竭的患者中,心房 natriuretic 和大脑 natriuretic 的不同分泌模式
M Yoshimura1, H Yasue, K Okumura
1Division of Cardiology, Kumamoto University School of Medicine, Japan.
Circulation
|February 1, 1993
概括
腹 natriuretic (ANP) 和大脑 natriuretic (BNP) 的血水平因心力衰竭的类型而异. BNP水平主要表明心室过载,而ANP和BNP分泌模式因特定的心脏状况而有所不同.
科学领域:
- 心脏病学 心脏病学
- 生物化学 生物化学
- 生理学 生理学 生理学
背景情况:
- 腹 natriuretic (ANP) 和大脑 natriuretic (BNP) 的血水平与充血性心力衰竭 (CHF) 的严重程度相关.
- 了解ANP和BNP分泌的变化对于管理CHF至关重要.
研究的目的:
- 为了调查ANP和BNP分泌模式在CHF患者中是否不同,基于潜在的心脏疾病.
- 评估不同CHF病因中的尿酸水平与心房和心室过载程度之间的关系.
主要方法:
- 进行了心脏导管治疗的20名患有心肌狭窄症 (MS),30名患有扩张性心肌病 (DCM) 和20名对照患者.
- 在大动脉中测量了ANP和BNP的血水平.
- 记录了肺毛细血管压 (PCWP) 和左心室末端透缩压 (LVEDP).
主要成果:
- 与对照组相比,MS和DCM组显示PCWP显著增加.
- 左心室末端透气压 (LVEDP) 在DCM显著高于MS.
- 与对照组相比,MS和DCM组的血ANP水平都较高,MS和DCM组之间没有显著差异.
- 血BNP水平在DCM中明显高于MS中,并且在MS中也高于对照组.
- 在DCM中,ANP和BNP都与PCWP正相关.
- 在MS中,ANP与PCWP相关,但BNP没有.
结论:
- 血BNP水平是心室过载的关键指标.
- ANP和BNP分泌模式受到特定心脏疾病的影响,以及CHF中心房和心室过载的程度.
相关概念视频
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...